Earnings Call · Q2 FY2022·2022-08-11

Q2 22EPS +14.29%·Rev n/aQ1 22EPS +24.14%·Rev n/aQ4 21EPS +12.31%·Rev n/aQ3 21EPS -100.00%*·Rev n/a⚠ consensus missing

Altimmune, Inc. ALT

Richard Eisenstadt — Investor Relations or Communications Officer

Vipin Garg — Chief Executive Officer

Scott Harris — Unclear but likely Senior Clinical or Medical Officer

+7.1%1d on move date+7.1% vs SPY3d+36.4%5d+33.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ALT calls or request research access.

More ALT calls Browse calls Request research access